Swine flu vaccine and multiple sclerosis.
Using age-specific rates for multiple sclerosis (MS) based on a national survey, the number of "naturally occurring" new cases of MS among the 45 million swine flu vaccine recipients in the United States is estimated as 1,624 during the year after vaccination, or 31 cases per week. Information from available reports and publications indicates no excess over the expected frequencies. Analyses of admissions for MS before, during, and after the immunization program showed no increase to the US Army hospitals or to the Mayo Clinic. Three independent controlled clinical investigations performed on patients with MS showed no increase in the frequency of exacerbations among those receiving swine flu vaccine as compared with those receiving placebo. Epidemiologic features of MS do not implicate killed virus vaccine as an etiologic factor in onset or exacerbations of the disease. There is no indication from these analyses of any association or cause-and-effect relationship between swine flu vaccine and MS.
D000328:Adult; D002986:Clinical Trials as Topic; D006801:Humans; D007114:Immunization / Q000009:adverse effects; D009980:Influenza A virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000009:adverse effects*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000453:epidemiology / Q000209:etiology*; D009976:Orthomyxoviridae Infections / Q000517:prevention & control; D014481:United States
D007252:Influenza Vaccines